![Glenn Michelson](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Glenn Michelson
Keine laufenden Positionen mehr
Profil
Glenn C.
Michelson is currently the Chief Medical Officer at Notable Labs Ltd. He previously held positions as the Director-Clinical Oncology Therapeutic Unit at Chiron Corp.
from 2004 to 2006, the Medical Director-Clinical Development at CTI BioPharma Corp., the Vice President-Clinical Development at CytomX Therapeutics, Inc. from 2019 to 2020, the Chief Medical Officer at Apollomics, Inc. (United States) from 2020 to 2021, the Chief Medical Officer at Plexxikon, Inc. from 2016 to 2018, the Vice President-Clinical Strategy at Sunesis Pharmaceuticals, Inc. from 2006 to 2011, and the Vice President-Clinical Development at Portola Pharmaceuticals LLC from 2018 to 2019.
Dr. Michelson obtained undergraduate, graduate, and doctorate degrees from the University of Louisville.
Aktive Positionen von Glenn Michelson
| Unternehmen | Position | Beginn |
|---|
Ehemalige bekannte Positionen von Glenn Michelson
| Unternehmen | Position | Ende |
|---|---|---|
Apollomics, Inc. (United States)
 Apollomics, Inc. (United States) BiotechnologyHealth Technology Develops mono therapies and combination therapies of tumor-targeting and immuno-oncology agents | Technik-/Wissenschafts-/F&E-Leiter | 16.03.2021 |
| CYTOMX THERAPEUTICS, INC. | Corporate Officer/Principal | 01.01.2020 |
| PORTOLA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.01.2019 |
Plexxikon, Inc.
 Plexxikon, Inc. Miscellaneous Commercial ServicesCommercial Services Provides clinical and medical drug discovery and development services | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2018 |
| VIRACTA THERAPEUTICS, INC. | Corporate Officer/Principal | 01.12.2011 |
Ausbildung von Glenn Michelson
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
63
Beziehungen ersten Grades
8
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 8 |
|---|---|
Chiron Corp.
 Chiron Corp. Medical SpecialtiesHealth Technology Provides nucleic acid test for blood screening | Health Technology |
CTI BioPharma Corp.
 CTI BioPharma Corp. Pharmaceuticals: MajorHealth Technology Engages in acquisition, development and commercialization of novel targeted therapies for blood-related cancers | Health Technology |
Plexxikon, Inc.
Plexxikon, Inc. Miscellaneous Commercial ServicesCommercial Services Provides clinical and medical drug discovery and development services | Commercial Services |
Sunesis Pharmaceuticals, Inc.
 Sunesis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops oncology therapeutics for treatment of solid and hematologic cancers | Health Technology |
Portola Pharmaceuticals LLC
 Portola Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Engages in development and commercialization of novel therapeutics | Health Technology |
University of Louisville
 University of Louisville Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
CytomX Therapeutics, Inc.
 CytomX Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as an oncology-base biopharmaceutical company, which focuses on developing probody therapeutics for the treatment of cancer | Health Technology |
Apollomics, Inc. (United States)
Apollomics, Inc. (United States) BiotechnologyHealth Technology Develops mono therapies and combination therapies of tumor-targeting and immuno-oncology agents | Health Technology |
